Skip to main content

Table 3 Event-free survival and its relation to different prognostic factors

From: Outcome and prognostic factors of pediatric patients with Hodgkin lymphoma: a single-center experience

Factors

 

EFS%

Median (months)

p-value

n

6 m

1 yr

2 yrs

3 yrs

(95% CI)

All

69

94.0

90.7

88.8

83.6

NA

NA

Gender

Male

57

96.4

92.5

90.3

83.8

NA

0.413

Female

12

81.8

81.8

81.8

81.8

NA

 

Age groups

0–5 yrs

13

92.3

92.3

92.3

92.3

NA

0.178

  > 5–10 yrs

29

96.4

92.4

92.4

92.4

NA

 

  > 10–15 yrs

21

95.2

95.2

89.9

80.0

NA

 

  ≥ 15 yrs

6

80

53.3

53.3

53.3

NA

 

ESR

  < 30

44

92.9

90.3

87.4

87.4

NA

0.997

  ≥ 30

25

96.0

90.4

90.4

76.2

NA

 

LN no

  < 3

40

100

100

96.9

96.9

NA

0.005

  ≥ 3

29

85.2

76.4

76.4

68.8

NA

 

Extra nodal

No

37

100

100

96.6

96.6

NA

0.013

Yes

32

87.1

79.5

79.5

70.7

NA

 

Splenic involvement

No

44

97.6

97.6

94.8

94.8

NA

0.013

Yes

25

87.5

77.7

77.7

66.6

NA

 

Bone marrow involvement

No

62

93.3

89.7

87.5

87.5

NA

0.950

Yes

7

100

100

100

80.0

NA

 

Lung involvement

No

63

93.5

91.8

89.9

84.6

NA

0.371

 Yes

6

100

66.7

NA

NA

NA

 

Bulky disease

No

56

94.4

90.4

88.1

80.1

NA

0.595

Yes

13

92.3

92.3

92.3

92.3

NA

 

Stage

I–II

33

100

96.2

96.2

96.2

NA

0.029

III–IV

36

88.2

81.4

81.4

73.3

NA

 

B symptoms

No

45

100

97.6

94.7

86.1

NA

0.059

Yes

24

82.6

77.1

77.1

77.1

NA

 

CMT

No

47

93.3

90.7

87.6

87.6

NA

0.909

Yes

22

95.5

90.9

90.9

83.3

NA

 

Histopathology subtypes

MC

29

100

100

100

100

NA

0.005

NS

36

88.2

81.7

78.0

66.8

NA

 

Radiotherapy dose

15

15

93.3

86.7

86.7

74.3

NA

0.196

20

7

100

100

100

100

NA

 

Interim PET-CT

No

60

93.2

91.4

91.4

84.8

NA

0.351

Yes

9

100

87.5

74.1

74.1

NA

 

Interim negative & CMT

No

43

100

90

90

90

80.7–99.2

0.719

Yes

17

94

94

88.2

88.2

72.9–100

 
  1. CMT combined modality treatment, MC mixed cellularity, NS nodular sclerosis, ESR erythrocyte sedimentation rate, LN lymph node, PET-CT positron emission tomography-computed tomography